Titre :

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

Auteur(s) :

Reboursiere, Emilie [Auteur]
CHU Caen
Le Bras, Fabien [Auteur]
Hôpital Henri Mondor
Herbaux, Charles [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gyan, Emmanuel [Auteur]
Clavert, Aline [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Malak, Sandra [Auteur]
Institut Curie [Paris]
Sibon, David [Auteur]
Imagine - Institut des maladies génétiques (IHU) [Imagine - U1163]
Broussais, Florence [Auteur]
Braun, Thorsten [Auteur]
Fornecker, Luc-Matthieu [Auteur]
Garidi, Reda [Auteur]
Tricot, Sabine [Auteur]
Houot, Roch [Auteur]
Joly, Bertrand [Auteur]
Abarah, Wajed [Auteur]
Choufi, Bachra [Auteur]
Pham, Anne-Dominique [Auteur]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Gac, Anne-Claire [Auteur]
Fruchart, Christophe [Auteur]
Marin, Emilie [Auteur]
CHU Caen
Safar, Violaine [Auteur]
Parcelier, Anne [Auteur]
CHU Amiens-Picardie
Maisonneuve, Herve [Auteur]
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon [CHD Vendée]
Bachy, Emmanuel [Auteur]
Cartron, Guillaume [Auteur]
Jaccard, Arnaud [Auteur]
Tournilhac, Olivier [Auteur]

Rossi, Cedric [Auteur]
Service d'Hématologie Clinique (CHU de Dijon)
Schirmer, Luciane [Auteur]
Martignoles, Jean-Alain [Auteur]
Gaulard, Philippe [Auteur]
Tilly, Herve [Auteur]
Groupe d'étude des proliférations lymphoïdes [GPL]
Damaj, Gandhi [Auteur]
Lymphoma Study Association Lysa, Centers [Auteur]

Titre de la revue :

Oncotarget

Nom court de la revue :

Oncotarget

Numéro :

7

Pagination :

85573-85583

Date de publication :

2016-12

ISSN :

1949-2553

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients.Between November 2009 and March 2015, ...
Lire la suite >Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients.Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population median age was 64 (28-89) years with male/female ratio of 1.4. There were mainly angio-immunoblastic (AITL = 71), PTCL-not otherwise specified (PTCL-NOS = 40) and anaplastic large cell lymphoma (ALCL = 8). The majority of patients (96%) had disseminated disease and extranodal localizations (77%). Median number of chemotherapy lines prior to bendamustine was 2 (1-8). Median duration of response (DoR) after the last chemotherapy prior to bendamustine was 4.3 months (1-70) and 50% of patients had refractory disease.Median number of administered bendamustine cycles was 2 (1-8) and 72 patients (52%) received less than 3 mostly because of disease progression. Median dose was 90 (50-150) mg/m². Overall response rate (ORR) was 32.6% with complete response (CR) rate of 24.6% and median DoR was 3.3 months (1-39). AITL patients were more sensitive than PTCL-NOS patients (ORR: 45.1 versus 20%, p = 0.01). Median PFS and OS were 3.1 (0.2-46.3) and 4.4 (0.2-55.4) months. On multivariate analysis, refractory disease (p = 0.001) and extranodal localization (p = 0.028) adversely influenced ORR. Grade 3-4 thrombocytopenia, neutropenia and infections were reported in 22, 17 and 23% of cases respectively.Bendamustine as single agent could be considered as a therapeutic option for relapsed or refractory PTCL, particularly in chemosensitive or AITL patients. Combinations of bendamustine with other drugs warrant further evaluation.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:07:22Z
2022-02-02T11:15:22Z